Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.

Autor: Fennell DA; Department of Medical Oncology, St Bartholomew's Hospital, London, United Kingdom., Steele JP, Shamash J, Slater SE, Sheaff MT, Wells P, Rudd RM, Stebbing J
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2007 Dec 01; Vol. 121 (11), pp. 2575-7.
DOI: 10.1002/ijc.22984
Abstrakt: There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m(2) Days 1 and 15 q28), cisplatin (40 mg/m(2) Days 1 and 15 q28) and mitomycin (6 mg/m(2) d1 q28) administered to a maximum of 6 cycles in individuals with rSCLC that had relapsed following first line treatment. Partial remissions were observed in 35% and progression in 30% of patients. Progression free survival measured 4.5 months (95% CI 0.8-8.2) and overall survival was 7.8 months (95% CI 5.3-10.3). QoL showed improvement in activity symptoms and stabilization of physical symptoms. As IPM was a well-tolerated regimen with activity in rSCLC, a phase III trial comparing this triplet with other regimens in this setting is warranted.
((c) 2007 Wiley-Liss, Inc.)
Databáze: MEDLINE
Externí odkaz: